Treatment of an Acquired Coagulopathy with Recombinant Activated Factor VII in a Damage-Control Patient

Authors: Holcomb, John B.¹; Hoots, Keith²; Moore, Fredrick A.³

Source: Military Medicine, Volume 170, Number 4, April 2005 , pp. 287-290(4)

Publisher: AMSUS - Association of Military Surgeons of the U.S.

Buy & download fulltext article:

Price: $20.00 plus tax (Refund Policy)

Abstract:

Recombinant activated factor VII is commonly used for the treatment of hemophiliac patients with inhibitors and has been studied for use in trauma. We report the use of recombinant activated factor VII for a male patient who was injured in a motor vehicle accident. We also summarize the animal studies and clinical trials that have been reported.

Document Type: Research article

Affiliations: 1: Department of Trauma and Critical Care, University of Texas Health Science Center, Houston, TX 77030 and Uniformed Services University of the Health Sciences, Bethesda, MD 20814. 2: Department of Pediatric Hematology, University of Texas Health Science Center, Houston, TX 77030. 3: Departments of Surgery and Trauma and Critical Care, University of Texas Health Science Center, Houston, TX 77030.

Publication date: 2005-04-01

More about this publication?

Military Medicine is the Association's official monthly journal. The objective of the Journal is to promote awareness of Federal medicine by providing a forum for responsible discussion of common ideas and problems relevant to Federal healthcare. Its mission is: To increase healthcare education by providing scientific and other information to its readers; to facilitate communication; and to offer a prestige publication for members' writings.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Membership Information
Information for Advertisers
Terms & Conditions
Reviewer Information
ingentaconnect is not responsible for the content or availability of external websites